Holen Sie sich die Stockscreener-App
2.41
3.60%
-0.09
Handel nachbörslich:
2.41
Elicio Therapeutics Inc Aktie (ELTX) Neueste Nachrichten
Why Is ELTX Stock Falling Today? - stocktwits.com
Pomerantz investigates Elicio Therapeutics after Phase 2 trial failure - scanx.trade
Elicio Therapeutics closes $15M registered direct offering - scanx.trade
Director at Elicio Therapeutics (ELTX) granted 21,750 stock options - Stock Titan
Director at Elicio Therapeutics (NASDAQ: ELTX) receives 21,750 stock options - Stock Titan
Director at Elicio Therapeutics (ELTX) granted 21,750 options at $2.70 - Stock Titan
Elicio Therapeutics | 4: Statement of changes in beneficial ownership of securities - Moomoo
Elicio Therapeutics (ELTX) director gets 21,750 options at $2.70 - Stock Titan
Director at Elicio Therapeutics (ELTX) gets 10-year stock option grant - Stock Titan
Director at Elicio Therapeutics (ELTX) gets 21,750 stock options - Stock Titan
Director at Elicio Therapeutics (ELTX) gets 21,750 options at $2.70 - Stock Titan
Ladenburg Thalmann assumes Elicio Therapeutics at Buy, target $12 - scanx.trade
Elicio Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference - Quiver Quantitative
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference - marketscreener.com
Schall Law investigates Elicio after Phase 2 trial failure - scanx.trade
HC Wainwright Has Bearish Forecast for ELTX Q3 Earnings - MarketBeat
Elicio (ELTX) Financial Update: Reported EPS Misses Expectations for This Review; Reaction Snapshot: Shares Move Higher 2.98% in Latest TradingShare Dilution Risk - Vinanet
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - Stocktwits
Elicio Therapeutics' (ELTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Elicio Therapeutics stock price target reiterated at $23 by H.C. Wainwright - Investing.com
H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $23 - Moomoo
JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Hold Rating - Moomoo
Elicio Therapeutics (ELTX) Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesBanking Earnings Report - Vinanet
ELTX Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentEstimate Dispersion - Vinanet
Elicio Therapeutics (NASDAQ:ELTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Elicio Therapeutics (ELTX) Stock Forum and Discussion - Moomoo
Elicio Therapeutics investigation follows Phase 2 failure - scanx.trade
Elicio Therapeutics: Q2 Earnings Snapshot - AOL.com
Elicio Therapeutics added to Russell 2000, 3000 indexes - scanx.trade
Elicio Therapeutics Q2 Results: EPS beats estimate, losses narrow 35% YoY - scanx.trade
Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results - MarketBeat
Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss - Stock Titan
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall - TradingView
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma - The Manila Times
Elicio Therapeutics Announces Opening of MSK-Led Phase 1 Neoadjuvant Study of ELI-002 7P in Resectable Pancreatic Cancer - Quiver Quantitative
Elicio Therapeutics Announces Activation of the - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therapeutics, Inc. (ELTX) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
ELTX Q2'26 Earnings: EPS estimate is (0.54) USD - TradingView
(ELTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Certain Stock Options of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. - marketscreener.com
Certain Warrants of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. - marketscreener.com
Certain Common Stock of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. - marketscreener.com
Elicio Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
ELTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Elicio Therapeutics (ELTX) Expected to Post Earnings on Thursday - MarketBeat
Elicio Therapeutics (NASDAQ:ELTX) Stock Price Down 1.7%Here's What Happened - MarketBeat
Price to sales ratio of Elicio Therapeutics, Inc – HAM:9HA - TradingView
Elicio Therapeutics Inc (ELTX) Cash Flow - TradingKey
ELTX|Elicio Therapeutics Inc|Price:3.000| - TradingKey
Elicio Therapeutics Inc (ELTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Elicio Therapeutics Inc (ELTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Elicio Therapeutics Market Sentiment - Benzinga
Elicio Therapeutics Inc (ELTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Elicio Therapeutics Inc (ELTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Elicio Therapeutics Q1 2026 Earnings: EPS Miss Highlights Ongoing Clinical-Stage ChallengesMargin Guidance - Vinanet
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):